# Expedited Safety Reporting Log -- ALC-19T (IND-XXXXXX)

> **SIMULATED DOCUMENT -- FOR PHARMA SIMULATION PURPOSES ONLY**
> All case IDs, dates, adverse events, and regulatory submissions described below are
> simulated. No real patient data or actual regulatory filings are represented.

---

**Product:** ALC-19T (anti-CD19 CAR-T, autologous)
**IND Number:** IND-XXXXXX (simulated)
**Study:** ALC19T-SLE-001 (Phase I, FIH, Refractory SLE)
**Regulatory Authority:** FDA (CBER)
**Applicable Regulation:** 21 CFR 312.32 -- IND Safety Reporting
**Reporting Period:** 15 October 2024 -- 14 February 2026 (cumulative)
**Log Maintained By:** Head of Patient Safety / Pharmacovigilance
**Last Updated:** 09 February 2026

---

## Reporting Requirements Summary

| Report Type | Regulatory Basis | Timeline | Trigger Criteria |
|-------------|-----------------|----------|------------------|
| 7-day IND Safety Report | 21 CFR 312.32(c)(2) | 7 calendar days from sponsor awareness | Fatal or life-threatening unexpected SUSAR |
| 15-day IND Safety Report | 21 CFR 312.32(c)(1) | 15 calendar days from sponsor awareness | Any unexpected SUSAR (serious, unexpected, and at least possibly related) |
| IND Annual Report / DSUR | 21 CFR 312.33; ICH E2F | Within 60 days of IND anniversary | Annual comprehensive safety review |
| Follow-up Report | 21 CFR 312.32(d) | As soon as relevant information available | New information on previously reported cases |

**Key Definitions:**
- **Serious (21 CFR 312.32(a)):** Death, life-threatening, hospitalization (or prolongation), disability/incapacity, congenital anomaly, or other important medical event
- **Unexpected:** Not listed (in nature, severity, or specificity) in the current Investigator's Brochure (Reference Safety Information)
- **SUSAR:** Suspected Unexpected Serious Adverse Reaction (serious + unexpected + at least possibly causally related)

---

## Expedited ICSRs (Individual Case Safety Reports)

| Case ID | Date Received | Awareness Date | Patient | Site | Dose Level | AE Term (MedDRA PT) | MedDRA SOC | CTCAE Grade | Seriousness Criteria | Causality (Inv.) | Expectedness | SUSAR? | Expedited Report Type | Regulatory Reference | FDA Submission Date | Submission Status | Follow-up Reports |
|---------|--------------|----------------|---------|------|-----------|---------------------|------------|-------------|---------------------|------------------|--------------|--------|----------------------|---------------------|--------------------|--------------------|-------------------|
| ALC19T-001-008 | 12-Jun-2025 | 12-Jun-2025 | 38/F | Site 001 | DL4 (5.0 x 10^6/kg) | Cytokine release syndrome | Immune system disorders | Grade 3 | Hospitalization (prolonged); important medical event | Related | Expected | No -- expected per IB | None required (expected SAE) | N/A | N/A -- logged as SAE only | F/U 1: 18-Jun-2025 (resolution) |
| ALC19T-003-015 | 28-Aug-2025 | 28-Aug-2025 | 41/F | Site 003 | DL5 (10.0 x 10^6/kg) | Pneumonia (Pseudomonas) | Infections and infestations | Grade 3 | Hospitalization | Possibly related | Expected | No -- expected per IB | None required (expected SAE) | N/A | N/A -- logged as SAE only | F/U 1: 05-Sep-2025 (resolution); F/U 2: 12-Sep-2025 (pathogen ID) |
| ALC19T-002-016 | 15-Oct-2025 | 15-Oct-2025 | 27/F | Site 002 | DL5 (10.0 x 10^6/kg) | Seizure (single, generalized tonic-clonic) | Nervous system disorders | Grade 3 | Hospitalization; important medical event | Related | **Unexpected** (seizure with ICANS Grade 1 background -- severity unexpected) | **Yes** | **15-day IND Safety Report** | **21 CFR 312.32(c)(1)** | **29-Oct-2025** | **Submitted (Day 14)** | F/U 1: 22-Oct-2025 (EEG results); F/U 2: 05-Nov-2025 (resolution, MRI normal) |
| ALC19T-001-018 | 03-Dec-2025 | 03-Dec-2025 | 45/M | Site 001 | DL5 (10.0 x 10^6/kg) | Ventricular tachycardia (sustained, requiring cardioversion) | Cardiac disorders | Grade 4 | Life-threatening; hospitalization (ICU) | Possibly related | **Unexpected** (not listed in IB as expected cardiac AE) | **Yes** | **7-day IND Safety Report** (life-threatening) + 15-day follow-up | **21 CFR 312.32(c)(2)** | **Initial: 09-Dec-2025 (Day 6); Complete: 17-Dec-2025 (Day 14)** | **Submitted (both)** | F/U 1: 10-Dec-2025 (cardiology consult); F/U 2: 17-Dec-2025 (resolution, echo normal); F/U 3: 07-Jan-2026 (30-day cardiac f/u clear) |
| ALC19T-003-019 | 22-Jan-2026 | 22-Jan-2026 | 33/F | Site 003 | DL5 (10.0 x 10^6/kg) | Macrophage activation syndrome / Haemophagocytic lymphohistiocytosis | Immune system disorders | Grade 4 | Life-threatening; hospitalization (ICU) | Related | **Unexpected** (HLH/MAS severity and presentation exceeded IB description) | **Yes** | **7-day IND Safety Report** (life-threatening) + 15-day follow-up | **21 CFR 312.32(c)(2)** | **Initial: 27-Jan-2026 (Day 5); Complete: 05-Feb-2026 (Day 14)** | **Submitted (both)** | F/U 1: 28-Jan-2026 (bone marrow biopsy confirming hemophagocytosis); F/U 2: 05-Feb-2026 (resolving with etoposide/dexamethasone); Pending: Final resolution report |

---

## Summary Statistics

| Metric | Count |
|--------|-------|
| Total SAEs reported in study | 5 |
| SAEs assessed as expected per IB | 3 |
| SAEs assessed as unexpected (SUSARs) | 3 |
| 15-day IND safety reports submitted | 1 (+ 2 combined with 7-day reports) |
| 7-day IND safety reports submitted | 2 |
| Reports submitted within regulatory timeline | 3/3 (100%) |
| Reports pending submission | 0 |
| Reports with outstanding follow-up | 1 (ALC19T-003-019 -- final resolution pending) |

---

## Regulatory Notifications

| Date | Action | Detail |
|------|--------|--------|
| 29-Oct-2025 | 15-day IND Safety Report | Case ALC19T-002-016: Unexpected seizure during ICANS. Submitted to FDA CBER via FDA ESG (electronic submissions gateway). Copy to all investigators and IRBs per 21 CFR 312.32(c)(1)(iii). |
| 09-Dec-2025 | 7-day IND Safety Report (initial) | Case ALC19T-001-018: Life-threatening ventricular tachycardia. Telephoned to FDA CBER Safety Reporting Portal + written IND Safety Report. |
| 17-Dec-2025 | 15-day follow-up report | Case ALC19T-001-018: Complete report with cardiology consultation, ECG tracings, echocardiogram results, and clinical resolution. |
| 27-Jan-2026 | 7-day IND Safety Report (initial) | Case ALC19T-003-019: Life-threatening HLH/MAS. Telephoned to FDA CBER + written IND Safety Report. DSMB emergency session convened. |
| 05-Feb-2026 | 15-day follow-up report | Case ALC19T-003-019: Complete report with bone marrow biopsy, cytokine panel (ferritin >50,000 ng/mL, sIL-2R elevated), treatment with etoposide/dexamethasone, patient improving. |

---

## DSMB Notifications

| Date | Trigger | DSMB Action |
|------|---------|-------------|
| 29-Oct-2025 | SUSAR: Seizure (ALC19T-002-016) | Unscheduled review. Recommended: continue enrollment with enhanced neurology monitoring (EEG at baseline and Day +7 for DL5). |
| 09-Dec-2025 | SUSAR: Ventricular tachycardia (ALC19T-001-018) | Unscheduled review. Recommended: add baseline ECG and troponin to DL5+ enrollment criteria; telemetry monitoring Days 0-7. Continue enrollment. |
| 27-Jan-2026 | SUSAR: HLH/MAS (ALC19T-003-019) | Emergency session. Recommended: temporary enrollment pause at DL5 pending completion of HLH case investigation. Resume enrollment after sponsor review of all DL5 cytokine data. |

---

## Investigator and IRB Notifications

Per 21 CFR 312.32(c)(1)(iii), all IND safety reports were distributed to:

- All participating investigators (3 sites)
- All reviewing IRBs/Ethics Committees (3 IRBs)
- Distribution confirmed within 24 hours of FDA submission for all reports

| Case ID | Investigator Notification Date | IRB Notification Date | Acknowledged |
|---------|-------------------------------|----------------------|--------------|
| ALC19T-002-016 | 29-Oct-2025 | 30-Oct-2025 | All 3 sites confirmed |
| ALC19T-001-018 | 09-Dec-2025 | 10-Dec-2025 | All 3 sites confirmed |
| ALC19T-003-019 | 27-Jan-2026 | 28-Jan-2026 | All 3 sites confirmed |

---

## Protocol Amendments Triggered by Safety Reports

| Amendment | Date | Trigger Case(s) | Change Description |
|-----------|------|-----------------|-------------------|
| Protocol Amendment 3 | Nov 2025 | ALC19T-002-016 | Added baseline EEG and Day +7 EEG for DL5 and above; added seizure history as exclusion criterion |
| Protocol Amendment 4 | Jan 2026 | ALC19T-001-018 | Added baseline ECG and cardiac troponin; added continuous telemetry monitoring Days 0-7 at DL5 and above; added known cardiac arrhythmia as exclusion criterion |
| Protocol Amendment 5 (pending) | Feb 2026 | ALC19T-003-019 | Under development: enhanced HLH/MAS monitoring with daily ferritin, sIL-2R at Days 0, +3, +7; H-Score calculation at any CRS Grade >= 2; etoposide available on-site for HLH management |

---

## Notes and Quality Assurance

- All ICSRs were entered into the safety database within 24 hours of initial receipt
  per SOP-PV-001 (ICSR Processing).
- Medical review of all cases was completed by the PV Physician within 48 hours per
  SOP-PV-003 (Medical Review of ICSRs).
- Expectedness assessment was performed against IB Version 1.0 (Reference Safety
  Information, dated September 2024).
- All expedited reports were prepared using the FDA MedWatch Form 3500A (CIOMS I format)
  and submitted via FDA Electronic Submissions Gateway (ESG).
- Case follow-up tracking is maintained in the PV database with automated alerts for
  outstanding follow-up at 30 and 60 days.

---

> **SIMULATED DOCUMENT -- FOR PHARMA SIMULATION PURPOSES ONLY**
> This log was generated as part of the Safety Research System pharma company simulation.
> All case IDs, dates, adverse events, regulatory submissions, and clinical details are
> entirely simulated for educational and platform demonstration purposes. No real patient
> data, actual FDA submissions, or proprietary information is contained herein.
